Kingsman Wealth Management Inc. Sells 9,142 Shares of Boston Scientific Corporation $BSX

Kingsman Wealth Management Inc. lowered its position in shares of Boston Scientific Corporation (NYSE:BSX) by 27.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 24,291 shares of the medical equipment provider’s stock after selling 9,142 shares during the quarter. Boston Scientific comprises approximately 1.3% of Kingsman Wealth Management Inc.’s portfolio, making the stock its 15th biggest position. Kingsman Wealth Management Inc.’s holdings in Boston Scientific were worth $2,372,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. FWL Investment Management LLC bought a new position in shares of Boston Scientific in the 2nd quarter worth about $26,000. Sound Income Strategies LLC grew its holdings in Boston Scientific by 90.9% in the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 120 shares during the period. Steph & Co. bought a new position in shares of Boston Scientific during the third quarter valued at approximately $25,000. 1248 Management LLC purchased a new position in shares of Boston Scientific during the first quarter valued at approximately $26,000. Finally, Kilter Group LLC purchased a new position in shares of Boston Scientific during the second quarter valued at approximately $30,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms recently weighed in on BSX. BTIG Research restated a “buy” rating and issued a $132.00 price target on shares of Boston Scientific in a research note on Friday, November 21st. Canaccord Genuity Group cut their target price on Boston Scientific from $132.00 to $131.00 and set a “buy” rating on the stock in a research note on Wednesday, December 17th. UBS Group restated a “buy” rating on shares of Boston Scientific in a report on Wednesday, December 17th. Wells Fargo & Company upped their price target on shares of Boston Scientific from $124.00 to $125.00 and gave the stock an “overweight” rating in a research note on Thursday, October 23rd. Finally, Oppenheimer raised shares of Boston Scientific from a “market perform” rating to an “outperform” rating and increased their price objective for the company from $118.00 to $125.00 in a research report on Monday, September 8th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Boston Scientific has an average rating of “Buy” and a consensus target price of $124.85.

Insider Buying and Selling

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $101.55, for a total value of $1,758,135.15. Following the completion of the sale, the executive vice president owned 23,600 shares of the company’s stock, valued at approximately $2,396,580. The trade was a 42.32% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Ellen M. Zane sold 12,891 shares of the stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total value of $1,266,927.48. Following the transaction, the director directly owned 24,134 shares in the company, valued at $2,371,889.52. The trade was a 34.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 93,095 shares of company stock worth $9,305,450. 0.50% of the stock is owned by insiders.

Boston Scientific Trading Up 0.2%

Boston Scientific stock opened at $95.98 on Wednesday. Boston Scientific Corporation has a one year low of $85.98 and a one year high of $109.50. The business’s fifty day moving average is $98.36 and its 200 day moving average is $101.05. The stock has a market capitalization of $142.28 billion, a PE ratio of 51.32, a price-to-earnings-growth ratio of 1.93 and a beta of 0.67. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.51 and a quick ratio of 0.96.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.71 by $0.04. The business had revenue of $5.07 billion for the quarter, compared to analysts’ expectations of $4.97 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The business’s revenue for the quarter was up 20.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. On average, sell-side analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.